Scientific Advisory Board

	Tom DeLaney, MD Dr. DeLaney is Professor of Radiation Oncology at Harvard Medical School, Co-Director of the Center for Sarcoma and Connective Tissue Oncology at Massachusetts General Hospital (MGH), and Medical Director of the Francis H. Burr Proton Therapy Center at MGH, where he specializes in treating chordomas and other tumors of the spine. He conducts clinical research involving novel forms of radiation therapy and radiosensitizers, and studies the role of hypoxia in radiation sensitivity.
	Adrienne Flanagan, MD, PhD Dr. Flanagan is Professor of Musculoskeletal Pathology at the University College London and Clinical Lead and consultant histopathologist at the Royal National Orthopaedic Hospital in Stanmore. She runs an active research program on bone cancer, and has made seminal discoveries about the molecular biology and genetics of chordoma. She collaborates with the Wellcome Trust Sanger Institute on the Chordoma Genome Project and is co-PI on the International Cancer Genomics Consortium bone cancer initiative.
	Fran Hornicek, MD, PhD Dr. Hornicek is Associate Professor in the Department of Orthopaedic Surgery at Harvard Medical School and Chief of the Orthopaedic Oncology Service at MGH, where he has one of the nation’s largest surgical practices for chordomas. He is also Co-Director of the Center for Sarcoma and Connective Tissue Oncology and director of the Stephan L. Harris Center for Chordoma Care at MGH. In these roles he leads a coordinated, cross-disciplinary chordoma research effort at MGH.
	Michael Kelley, MD Dr. Kelley is Associate Professor of Medicine at Duke University and Chief of Hematology and Oncology at the Durham VA Medical Center. His lab has a major focus in chordoma, and in collaboration with colleagues at the National Cancer Institute has identified brachyury as a cause of familial chordoma.
	Paul Meltzer, MD, PhD Dr. Meltzer is a medical oncologist and Chief of the Genetics Branch of the Center for Cancer Research at the National Cancer Institute. He is regarded as a leading expert in cancer genomics, and has led major genomic profiling projects for multiple tumor types including sarcomas, melanoma and breast cancer.
	Deric Park, MD Dr. Park is Assistant Professor in the Department of Neurological Surgery at the University of Virginia, where he provides medical care for patients with brain tumors and directs the Laboratory of Brain Tumor Biology. He serves as principal investigator of a multi-center clinical trial for chordoma, and his research aims at developing novel treatments for chordoma.
	Neil Spector, MD Dr. Spector is Associate Professor and Director of Translational Research in Oncology at Duke University, where he focuses on developing targeted cancer therapies with a special emphasis on rare cancers. In his previous position as director of Exploratory Medical Sciences in Oncology at GlaxoSmithKline, he led the development of two new cancer drugs: Nelarabine and Tykerb.